MVIR — Medivir AB Share News
0.000.00%
Last trade - 00:00- SEK896.01m
- SEK642.51m
- SEK8.51m
Brief: Medivir Announces Partially Guaranteed Rights Issue Of About Sek 148 Mln
Brief: Medivir Q3 Revenue at SEK 800 Thousand
Brief: Medivir's Treatments Show Tumor Control In HCC, Patients Handle Two Cycles
Brief: Medivir's Partner Tango Therapeutics Receives FDA Clearance
Brief: Medivir's Partner Tango Therapeutics Received FDA Clearance To Start The TNG348 Phase 1/2 Clinical Study
Brief: Medivir: Promising Interim Data, First Complete Response In Phase 1b/2a HCC Study With Fostrox In Combination With Lenvima
Brief: Medivir Says Existing Cash To Meet Liquidity Needs Until Q2 2024
Brief: Medivir Partners With Liver Cancer Experts In Scientific Advisory Council
Brief: Medivir's Patent Application For Fostrox Approved In China
Brief: Medivir Q1 EBITDA Loss SEK 18.9 Mln
Brief: Medivir Q1 Revenue SEK 0.4 Million
Brief: Medivir Q4 Revenue SEK 2.3 Million
Brief: Medivir Partner Infex Therapeutics Receives FDA QIDP Designation
Brief: Medivir Completes Successful Pre-Ind Meeting With FDA
Brief: Medivir Q3 EBITDA Loss Widens To SEK 13.9 Million
Brief: Medivir To Present Data At SITC 2022 Annual Meeting
Brief: Medivir Q2 EBITDA Loss Widens To SEK 21.5 Mln
Brief: Medivir Q1 EBITDA Loss Widens To Sek 31.4 Million
Brief: Medivir's MIV-711 For Osteoarthritis Study Shows Reduction In Pain